Streptococcus pneumoniae is among the deadliest infectious disease agents across the world. Despite advancements in vaccine technology over the last few decades, S. pneumoniae continues to manifest as high hospitalization and mortality rates. Our goal at Pneumotactix is to develop therapeutics and vaccines that can significantly improve patient resistance to pneumococcal infections.

The immune system is the human body’s greatest weapon in the fight against infectious diseases. As such, we strive to find ways to improve the immune response against pneumococcal diseases. Current therapies in development include enzymatic degradation of the  capsular polysaccharide, the bacterium's major infectivity factor. We also develop monoclonal antibodies against S. pneumoniae that promote the clearance of the bacteria.

Our studies are currently in pre-clinical stages. We collaborate with drug discovery experts, pulmonologists and epidemiologists to optimize drug availability and production, advance our cutting edge therapies to the clinic, and significantly reduce pneumococcal infections and mortality.